Rapid Screening for Olfactory Disorders in Covid-19 Infection

Olfaction Disorders Clinical Trial

— OLFASCAN  

Official title:

Rapid Screening for Olfactory Disorders in Covid-19 Infection

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04696601
• Other study ID #: 20-PP-27
• Status: Withdrawn
• Phase: N/A
• Start date: January 8, 2021
• Est. completion date: January 1, 2023

Study information

• Verified date: December 2020
• Source: Centre Hospitalier Universitaire de Nice
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Loss of smell is very frequently found in Europe during Covid-19 attack. This symptom was not initially expected as part of the classic symptomatology. This loss of smell mainly concerns patients with few or no symptoms, without criteria of severity and usually treated on an outpatient basis. As a result, given the unexpected occurrence of this symptom (with less awareness in the general and medical population) and the potential risk of contamination of Covid+ and anosmic subjects (due to their less symptomatic form), it is interesting to be able to propose large-scale screening for loss of sense of smell in order to preferentially direct subjects diagnosed as anosmic towards RT-PCR-type screening. In the medium term, the loss of smell seems to persist after the infectious phase, with delayed or persistent recovery, which can lead to negative psychological repercussions.

The objective is to propose large-scale screening of the general population for loss of sense of smell during a pandemic period, in order to facilitate diagnostic orientation of the population. The diagnosis of loss of smell will be carried out using a simple olfactory test in the form of an olfactory stick to be smelled.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 1, 2023
• Est. primary completion date: January 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject presenting himself at the covid-19 screening centre set up by the city of Nice

Exclusion Criteria:

• Presence of a sensory deficit (auditory or visual) preventing the subject from answering the questions perfectly during the olfactory test.

• Subject receiving cancer chemotherapy

Related Conditions & MeSH terms

• COVID-19
• COVID-19 Testing
• Olfaction Disorders

Intervention

Diagnostic Test:
• Olfactory test
The olfactory test (Olfascan) is in the form of a paper stick, previously impregnated with an odorant (non-liquid). It is placed a few centimetres from the participant's nose at the time of the test. It is a single-use test, without contact with the participant.

Locations

Country	Name	City	State
France	CHU de Nice	Nice

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Olfactory test	Sensitivity of the olfactory test (Olfascan) for measuring anosmia, compared to the reference diagnostic test (RT-PCR analysis).	Day 0